Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 760.5 g/mol |
|---|---|
| Molecular Formula | C31H36Cl2F6N4O5P- |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 8 |
| Exact Mass | 759.1704566 g/mol |
| Monoisotopic Mass | 759.1704566 g/mol |
| Topological Polar Surface Area | 106 A^2 |
| Heavy Atom Count | 49 |
| Formal Charge | -1 |
| Complexity | 1100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 1 | |
|---|---|
| Drug Name | AKYNZEO |
| Active Ingredient | FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE |
| Company | HELSINN HLTHCARE (Application Number: N210493) |
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The approval is based on results of a Phase III clinical study (CONSOLE6) comparing the efficacy and safety of Arokaris® versus fosaprepitant in patients receiving highly emetogenic chemotherapy in combination with palonosetron and dexamethasone.
Lead Product(s): Fosnetupitant Chloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Arokaris
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fosnetupitant Chloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris®...
Details : The approval is based on results of a Phase III clinical study (CONSOLE6) comparing the efficacy and safety of Arokaris® versus fosaprepitant in patients receiving highly emetogenic chemotherapy in combination with palonosetron and dexamethasone.
Product Name : Arokaris
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Taiho Pharmaceutical has submitted to the Japanese Ministry of Health, Labour and Welfare a new drug application for an NK1 receptor antagonist antiemetic drug for gastrointestinal symptoms (nausea and vomiting) associated with cancer chemotherapy.
Lead Product(s): Fosnetupitant Chloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Arokaris
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 23, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fosnetupitant Chloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Taiho Pharmaceutical has submitted to the Japanese Ministry of Health, Labour and Welfare a new drug application for an NK1 receptor antagonist antiemetic drug for gastrointestinal symptoms (nausea and vomiting) associated with cancer chemotherapy.
Product Name : Arokaris
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 23, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.
Lead Product(s): Fosnetupitant Chloride,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Helsinn Advanced Synthesis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 27, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fosnetupitant Chloride,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 27, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE
Brand Name : AKYNZEO
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL
Packaging :
Approval Date : 2018-04-19
Application Number : 210493
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE
Brand Name : AKYNZEO
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)
Packaging :
Approval Date : 2020-05-27
Application Number : 210493
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride
Brand Name : Akynzeo
Dosage Form : Concentrate For Solution For Infusion
Dosage Strength : 235mg/0.25mg
Packaging :
Approval Date : 12/11/2021
Application Number : 20200916000079
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride
Brand Name : Akynzeo
Dosage Form : Powder For Concentrate For Solution For Infusion
Dosage Strength : 235mg/0.25mg
Packaging :
Approval Date : 16/03/2020
Application Number : 20181108000049
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Palonosetron Hydrochloride; Fosnetupitant
Brand Name : Akynzeo
Dosage Form : Powder For Concentrate For Solution For Infusion
Dosage Strength : 235MG; 0.25 MG
Packaging :
Approval Date : 2020-06-10
Application Number : 1151001003
Regulatory Info : Authorized
Registration Country : Spain

Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Akynzeo IV
Dosage Form : Concentrate For Solution For Infusion
Dosage Strength : 235mg;0.25mg
Packaging :
Approval Date : 01/09/2022
Application Number : 68290
Regulatory Info : Allowed
Registration Country : Switzerland

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE
Brand Name : AKYNZEO
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL
Approval Date : 2018-04-19
Application Number : 210493
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE
Brand Name : AKYNZEO
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)
Approval Date : 2020-05-27
Application Number : 210493
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride
Brand Name : Akynzeo
Dosage Form : Concentrate For Solution For Infusion
Dosage Strength : 235mg/0.25mg
Packaging :
Approval Date : 12/11/2021
Application Number : 20200916000079
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride
Brand Name : Akynzeo
Dosage Form : Powder For Concentrate For Solution For Infusion
Dosage Strength : 235mg/0.25mg
Packaging :
Approval Date : 16/03/2020
Application Number : 20181108000049
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Palonosetron Hydrochloride; Fosnetupitant
Brand Name : Akynzeo
Dosage Form : Powder For Concentrate For Solution For Infusion
Dosage Strength : 235MG; 0.25 MG
Packaging :
Approval Date : 2020-06-10
Application Number : 1151001003
Regulatory Info : Authorized
Registration Country : Spain

Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Akynzeo IV
Dosage Form : Concentrate For Solution For Infusion
Dosage Strength : 235mg;0.25mg
Packaging :
Approval Date : 01/09/2022
Application Number : 68290
Regulatory Info : Allowed
Registration Country : Switzerland

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
80
PharmaCompass offers a list of Fosnetupitant Chloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fosnetupitant Chloride manufacturer or Fosnetupitant Chloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fosnetupitant Chloride manufacturer or Fosnetupitant Chloride supplier.
PharmaCompass also assists you with knowing the Fosnetupitant Chloride API Price utilized in the formulation of products. Fosnetupitant Chloride API Price is not always fixed or binding as the Fosnetupitant Chloride Price is obtained through a variety of data sources. The Fosnetupitant Chloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fosnetupitant Chloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fosnetupitant Chloride, including repackagers and relabelers. The FDA regulates Fosnetupitant Chloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fosnetupitant Chloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fosnetupitant Chloride supplier is an individual or a company that provides Fosnetupitant Chloride active pharmaceutical ingredient (API) or Fosnetupitant Chloride finished formulations upon request. The Fosnetupitant Chloride suppliers may include Fosnetupitant Chloride API manufacturers, exporters, distributors and traders.
click here to find a list of Fosnetupitant Chloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fosnetupitant Chloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Fosnetupitant Chloride active pharmaceutical ingredient (API) in detail. Different forms of Fosnetupitant Chloride DMFs exist exist since differing nations have different regulations, such as Fosnetupitant Chloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fosnetupitant Chloride DMF submitted to regulatory agencies in the US is known as a USDMF. Fosnetupitant Chloride USDMF includes data on Fosnetupitant Chloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fosnetupitant Chloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fosnetupitant Chloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fosnetupitant Chloride Drug Master File in Japan (Fosnetupitant Chloride JDMF) empowers Fosnetupitant Chloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fosnetupitant Chloride JDMF during the approval evaluation for pharmaceutical products. At the time of Fosnetupitant Chloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fosnetupitant Chloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Fosnetupitant Chloride Drug Master File in Korea (Fosnetupitant Chloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Fosnetupitant Chloride. The MFDS reviews the Fosnetupitant Chloride KDMF as part of the drug registration process and uses the information provided in the Fosnetupitant Chloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Fosnetupitant Chloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Fosnetupitant Chloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Fosnetupitant Chloride suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fosnetupitant Chloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fosnetupitant Chloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fosnetupitant Chloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fosnetupitant Chloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fosnetupitant Chloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fosnetupitant Chloride suppliers with NDC on PharmaCompass.
Fosnetupitant Chloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fosnetupitant Chloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fosnetupitant Chloride GMP manufacturer or Fosnetupitant Chloride GMP API supplier for your needs.
A Fosnetupitant Chloride CoA (Certificate of Analysis) is a formal document that attests to Fosnetupitant Chloride's compliance with Fosnetupitant Chloride specifications and serves as a tool for batch-level quality control.
Fosnetupitant Chloride CoA mostly includes findings from lab analyses of a specific batch. For each Fosnetupitant Chloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fosnetupitant Chloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Fosnetupitant Chloride EP), Fosnetupitant Chloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fosnetupitant Chloride USP).